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Cystic Fibrosis (CF) lung disease is characterised by a chronic and
exaggerated inﬂammation in the airways. Despite recent develop-
ments to therapeutically overcome the underlying functional de-
fect in CFTR (cystic ﬁbrosis transmembrane conductance regulator),
there is still an unmet need to also normalise the inﬂammatory
response. The prolonged and heightened inﬂammatory response
in CF is in part mediated by a lack of intrinsic downregulation
of the pro-inﬂammatory NF-kB pathway. We have previously
identiﬁed reduced expression of the NF-kB down-regulator A20
in CF as a key target to normalise the inﬂammatory response.
Here we have used publically available gene array expression data
together with sscMap (statistically signiﬁcant connections’map) to
successfully predict drugs already licensed for the use in humans
to induce A20 mRNA and protein expression and thereby reduce
inﬂammation. The effect of the predicted drugs on A20 and NF-
kB(p65) expression (mRNA) as well as pro-inﬂammatory cytokine
release (IL-8) in the presence and absence of bacterial LPS was
shown in bronchial epithelial cells lines (16HBE14o-, CFBE41o-)
and in primary nasal epithelial cells (PNECs) from patients with
CF (Phe508del homozygous) and non-CF controls. Additionally, the
speciﬁcity of the drug action on A20 was conﬁrmed using cell lines
with TNFAIP3 (A20) knockdown (siRNA). We also show that the
A20 inducing effect of ikarugamycin and quercetin is lower in CF
derived airway epithelial cells than in non-CF cells.
A20 (TNFAIP3) j NF-kappaB j Connectivity Mapping j Drug reposition-
ing j CF airway inﬂammation
Introduction
The response to pathogens, recognised by pattern recognition
receptors including Toll-like receptors (TLRs), triggers an acute
innate immune response that is mediated by transcription factors
such as nuclear factor-kappa-light-chain enhancer of B cells (NF-
κB). NF-κB activation promotes the transcription of inflamma-
tory mediators in a tightly regulated process. However, in indi-
viduals with underlying chronic inflammatory diseases, this reg-
ulation is compromised, leading to constitutive NF-κB activation
and persistent inflammation (1-3)
The development of new first-in-class medicines is costly
(approximately $1.2 billion for a single FDA-approved drug) and
takes between 10 and 15 years (4, 5).Many newly developed drugs
perform well in the preclinical testing, but fail when tested in
humans (6). Thus alternative approaches using predictive models
to identify new drugs are needed. Gene expression connectivity
mapping (www.broadinstitute.org/cmap/) is an advanced bioin-
formatics technique to establish the connections among biolog-
ical states via gene expression profiles/signatures. One major
application of connectivity mapping is to identify potential small
molecules able to inhibit a disease state or regulate the expres-
sion of a small number of genes (7-9). We used an advanced
version of connectivity mapping, sscMap (statistically significant
connections’ map) (10), which has been successfully applied to
phenotypic targeting and predicting effective drugs in cancer (10).
However, this has not yet been applied to chronic inflammatory
diseases.
Cystic Fibrosis (CF) is a chronic multi-organ inflammatory
disease, caused by mutations in the CFTR gene (Cystic Fibro-
sis Transmembrane Conductance regulator) expressed on apical
epithelial surfaces. It is the most common lethal genetic disease
in Caucasian populations. Lung disease is the primary cause
of morbidity and mortality in CF, resulting from dehydration
of epithelial surfaces and reduced mucociliary clearance as a
consequence of the ionic imbalance created by CFTR mutation.
This leads to a cycle of infection and inflammation associated with
a progressive reduction in lung function and eventual respiratory
failure. A common feature of CF is the heightened, chronic in-
flammatory response to Pseudomonas aeruginosa (P. aeruginosa),
driven by constitutive NF-κB activation in airway and peripheral
blood cells (2, 3, 11). Primary nasal epithelial cells (PNECs)
from patients with the common F508del/F508del mutation and
a milder genotype (R117H/F508del), show a significant increase
in NF-κB(p65) which correlates with disease severity (12).
A20 (TNFAIP3) is a central negative regulator of NF-κB
activation following stimulation of TLRs and/or TNF-receptor
and regulates different signalling pathways such as NF-kB and
interferon regulatory factor (IRF) signalling (13). A20 modifies
Signiﬁcance
This study reports that publically available gene array expres-
sion data together with statistically signiﬁcant connections’
map (sscMap) can successfully predict already licensed drugs
to modify genes of interest. We applied this bioinformatics
approach to the NF-kB regulator A20 (TNFAIP3), which is re-
duced in Cystic Fibrosis (CF) airway cells. sscMap predicted
drugs that should induce A20 and normalise the inﬂammatory
response in CF. Using airway epithelial cells we show that
ikarugamycin and quercetin have anti-inﬂammatory effects
mediated by induction of A20. Using siRNA we conﬁrm that
the anti-inﬂammatory effect of ikarugamycin and quercetin
are mainly due to A20 induction. We have identiﬁed a process
whereby already licensed drugs can be successfully reposi-
tioned for chronic inﬂammatory airway diseases.
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Table 1.
ID of data
set
Sample Type Platform used Sample size Published in
GSE2395 Primary nasal
epithelial
cells (PNECs)
HG-U133A &
HG-U133B:
GPL96/GLP97
40 (18 CF fF508del
homozygousg, 22
controls), exposed to P.
aeruginosa
Wright JM et al.
2006
GSE30439 CFBE41o- HG-U133 Plus2:
GPL570
12 (CFBE41o- and
CFBE41o- complemented
with wildtype CFTR), +/-
exposure to PA01
Hampton TH et
al. 2012
GSE620 IB3-1 HG-U133A:
GPL96
5 (IB3-1cells, excluded
those with
4-phenylbutyrate
treatment)
Wright JM et al.
2004
GSE923 Calu-3 HG-U133A:
GPL96
19 (Calu-3
fF508del/F508delg
infected with P.
aeruginosa (mucoid vs.
motile strain)
Cobb LM et al. J
Immunol 2004
Table 2.
Gene symbol Unique ID Name Function
TNFAIP3 202643 s at A20 Ubiquitination, negative regulator of NF-kB
ATF3 202672 s at Activating
Transcription
Factor 3
Binds the cAMP response element (CRE),
transcriptional repressor (promoters with
ATF sites)
RAB5C 201140 s at RAB5C small GTPase, regulates membrane trafﬁc
from plasma membrane to early endosomes,
ubiquitously expressed
DENND4A 214787 at DENN/MADD
domain
containing 4A
C-myc promoter-binding protein, promotes
exchange of GDP to GTP, converting inactive
GDP-bound Rab proteins into their active
GTP-bound form
classical immune cells (14, 15) as well as epithelial cells (12),
endothelial cells (16), embryonic fibroblasts (17), osteoclasts (18)
and pancreatic beta-cells (19) and diverse roles for A20 in innate
immunity, apoptosis, autophagy and antigen processing (13, 15,
16, 20). Within the innate inflammatory immune response A20
regulates NF-κB signalling at the level of TRAF6 in mouse em-
bryonic fibroblasts (MEFs) and osteoclasts (17, 18). In cultured
human airway epithelial cells, A20 is rapidly induced by viral or
bacterial compounds (21) and is essential for termination of the
TLR4 signal (22). PNECs stimulated with P. aeruginosa LPS show
a transient increase in A20, but CF PNECs display lower A20
expression basally and after LPS stimulation (12, 23).
Therefore, A20 induction should have anti-inflammatory ef-
fects within the tightly regulated NF-kB signalling pathway as
shown by the induction of A20 through gibberellin (GA3) in
airway epithelial cells. GA3 induced A20, reduced IL-8 secretion,
stabilised cytosolic IkBα and reduced NF-κB (p65) activation
(24). Here we set out to identify additional compounds able to
induce A20. Thus, we performed a compound search using gene
expression connectivity mapping to identify existing drugs that
could induce A20 expression.
Results
1. Connectivity mapping (sscMap):
The selection of gene array data and creation of the gene signature
Data sets that passed the selection criteria contained human
primary nasal epithelial cells (PNECs) and the human bronchial
epithelial cell lines CFBE41o-, Calu-3 and IB3-1 analysed basally
and after exposure to P. aeruginosa LPS (Table 1). In total 76
samples from4different published gene array data sets were used.
Linear expression correlation and GO enrichment analysis for
NF-κB pathway genes identified the closest correlates to A20.
Table 2 shows the top 7 genes that subsequently served as the input
to the connectivity mapping process.
Prediction of drugs to induce A20 in airway epithelial cells
This study sought small molecular compounds that may en-
hance A20 expression and as a confirming negative control, those
compounds that may inhibit A20 expression. Table 3 summa-
rizes the top candidate drugs identified. The column entitled
‘significance’ shows the significance of drugs based on p values
and the column ‘z-score’ shows the correlation of the drugs with
the input gene signature. Positive z-scores indicate a positive
correlation i.e. the input genes are induced when treated with the
particular drug. The significant drugs with the highest positive
z-scores along with a negative control were selected for labo-
ratory validation. In addition to p values and z scores, stability
of the connections was measured by altering the gene signature
and the significance of the connections are given under the
column ‘perturbation stability’. Drugs with perturbation stability
1 represent strong connections which remain significant with
‘perturbation’ gene signatures. From these predictions two A20
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Fig. 1. Gene expression proﬁle of the gene signature genes associated with
A20. 16HBE14o- (grey) and CFBE41o- (green) were stimulated (LPS, 10 μg/ml
0-24 h) and mRNA levels of A20, ATF3, Rab5c, DENNDA4, POM121, ICAM-
1 and PSNE1 determined as described. $ signiﬁcant difference compared to
medium control, * signiﬁcant differences between genotypes.
inducing drugs (ikarugamycin and quercetin) as well as one non-
A20 inducing drug (fluvastatin) were chosen for further investi-
gation.
2. Gene expression of gene signature
Expression of the genes identified as the A20/NF-kB gene
signature in CF epithelial cells were analysed by qRT-PCR in
16HBE14o- and CFBE41o- cultured in the presence or absence
of LPS for 0-24h (Figure 1).
Basal expression: CFBE41o- show significantly lower mRNA
expression for A20, ATF3, Rab5c and ICAM1 compared to
16HBE14o- (all p<0.05, n=5). Expression of DENNDA4 and
PSNE1 was also lower in CFBE41o- but this did not reach sig-
nificance.
LPS induced expression: In 16HBE14o-, A20 mRNA is rapidly
induced with expression peaking 1h after LPS exposure (p<0.001
compared to medium, n=5), while CFBE41o- show significantly
lower (at 1h p<0.001 vs. 16HBE14o-, n=5) and delayed (maximal
induction at 4-8 h, p<0.01 and 0.001 vs. medium, n=5) induction
upon LPS stimulation. After LPS, ATF3 and ICAM1 expression
was significantly lower in CFBE41o- compared to 16HBE14o-
Fig. 2. A20 and p65 mRNA expression of ikarugamycin, quercetin and
ﬂuvastatin treated cells. 16HBE14o- and CFBE41o- were pre-incubated with
(a) ikarugamycin, (0.01, 1 μM), (b) quercetin (0.1, 100 μM) or (c) ﬂuvastatin
(0.1, 1 μM) stimulated (LPS, 10 μg/ml, 0-24 h), A20 mRNA determined (qRT-
PCR) and expressed as A20/β-actin relative to the internal control.
(p<0.01, n=5). Pom121 and PSNE1 expression increased in
CFBE41o- compared to medium (8h, p<0.05 and p<0.01) and in
CFBE41o- compared to 16HBE14o- (8h, p<0.05 and p<0.001).
16HBE14o- showed a significant reduction in DENNDA4 and
Rab5c expression compared to medium (1h, p<0.05 and 4h,
p<0.05, respectively), but there was no significant change in the
expression of these genes in CFBE41o-.
3. Effect of A20 inducing drugs on cell lines
LDH release in drug exposed 16HBE14o- and CFBE41o-:
LDH release was measured after exposure to the drugs alone
(0.01–1000 µM) and with LPS stimulation (supplement Figure 1S).
Quercetin did not cause any LDH release. Overall fluvastatin
was almost without effect on LDH; the exceptions were a slight
but statistically significant increase at 10 µM alone (CFBE41o-
) and in the presence of LPS (in CFBE41o- and 16HBE14o-
). Ikarugamycin (1, 100 µM) caused a significantly higher LDH
release in both cell types. In LPS stimulated cells, 0.1 μM
ikarugamycin and higher concentrations showed a higher LDH
release compared to LPS alone, but this did not reach statistical
significance (supplement Figure 1S).
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Fig. 3. Effect of ikarugamycin, quercetin and ﬂuvastatin on A20 and p65
protein expression. 16HBE14o- and CFBE41o- were pre-incubated with (a)
ikarugamycin, (0.01, 1 μM), (b) quercetin (0.1, 100 μM) or (c) ﬂuvastatin (0.1,
1 μM) and stimulated (LPS, 10 μg/ml, 0-24 h). Cytosolic A20 and p65 protein
was determined byWestern Blotting: 1 = Ctr, 2 = LPS, 3 = drug at lower conc.,
4 = drug at lower conc. + LPS, 5 = drug at higher conc., 6 = drug at higher
conc., + LPS.
LPS stimulated IL-8 release in drug pre-treated 16HBE14o-
and CFBE41o-: To assess the anti-inflammatory potential of the
selected drugs, cells were pre-treated with the drug for 1h, stim-
ulated with LPS and the IL-8 release measured and the rela-
tive IC50 calculated (supplement S3). In 16HBE14o-, all drugs
reduced IL-8 release by at least 50% with an IC50 of 15.6 μM for
ikarugamycin, 0.09 μM for quercetin and 0.11 μM for fluvastatin.
In CFBE41o-, only quercitin (IC50 0.03 μM) and fluvastatin (IC50
0.001 μM) pre-treatment were able to reduce release by 50%. In
contrast, pre-treatment of CFBE41o- with 1 μM ikarugamycin
caused a significant increase in IL-8 release compared to LPS
alone (LPS 269.9 ± 47.9 pg/ml vs. 590.7 ± 82.6 pg/ml, p<0.05,
n=5). Therefore, a meaningful calculation of the relative IC50
for IL-8 release in ikarugamycin treated CFBE41o- cells was not
possible.
A20mRNA induction in drug treated 16HBE14o- and CFBE41o-
: To elucidate if ikarugamycin and quercetin facilitate their anti-
inflammatory action though the induction of A20 as predicted,
Fig. 4. The anti-inﬂammatory effect of ikarugamycin and quercetin is
mediated by A20 induction. 16HBE14o- with and without knock-down of
A20 were pre-incubated with ikarugamycin, (1 μM) or quercetin (100 μM),
stimulated and IL-8 analysed. Drug treatment caused a signiﬁcant reduction
in IL-8 (p<0.05) compared to LPS stimulation alone. A20 knock-down resulted
in a lack of the anti-inﬂammatory effect of the drug tested.
A20 mRNA was determined by qRT-PCR. Fluvastatin was in-
cluded as a negative control. Using the LDH and IL-8 release
data two drug concentrations were selected for further investi-
gations (supplement S3). In 16HBE14o-, LPS stimulation caused
a significant induction of A20 1h after stimulation (Figure 2).
Ikarugamycin (0.01 µM) alone did not cause a significant induc-
tion of A20, but additional LPS stimulation caused a significant
A20 induction at 24h (p<0.05 vs LPS 24h). 1 μM ikarugamycin
significantly induced A20 at 4h on its own, but the higher A20
expression in the presence of LPS (1-24h) did not reach statistical
significance. Quercetin pre-treatment did not induce significant
levels of A20 mRNA at 0.1 μM, alone or in the presence of
LPS. However, at 100 μMquercetin A20 mRNAwas significantly
induced alone at 1h and 4h (p<0.05 vs. medium 1h and 4h) and in
the presence of LPS at 4h (p<0.05 vs. LPS 4h). Fluvastatin alone
did not induce A20 mRNA at any time or concentration (Figure
2), in the presence of LPS fluvastatin pre-treatment caused a
significant reduction in A20mRNA at both concentrations tested
(p<0.001 for 0.1 μM+LPS 1h vs. LPS 1h; p<0.05 for 1 μM+LPS
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Fig. 5. Effect of ikarugamycin, quercetin and ﬂu-
vastatin on IL-8 release from PNECs from (a) healthy
controls and (b) patients with CF. The release of IL-
8 (pg/ml) was determined using a commercially avail-
able IL-8 ELISA kit.Statistical analysis was performed
using Wilcoxon paired ranked t-test.
1h vs. LPS 1h). In CFBE41o-, LPS significantly induced A20 at
4h (p<0.05), but induction levels were lower than in 16HBE14o-
(Figure 2). Ikarugamycin (1 µM) induced significant levels of A20
at 4h and 24h (both p<0.05), this was further increased in the
presence of LPS at 4h (p<0.05 vs LPS 4h) and 24h (p<0.01 vs
LPS 24h). Quercetin treatment alone significantly induced A20
at 4h at both concentrations (p<0.05 0.1 μM vs. medium 4h and
p<0.01 100 μM vs. medium 4h). In the presence of LPS, only
100 μM quercetin caused a significant induction of A20 at 24h
(p<0.05). Fluvastatin alone did not induce A20 mRNA at any
time or concentration (Figure 2), and in the presence of LPS
fluvastatin caused a significant reduction in A20 mRNA at both
concentrations tested (p<0.05 for 0.1 μM+LPS 4h vs. LPS 4h;
p<0.05 for 1 μM+LPS 4h vs. LPS 4h).
Effect of selected components on NF-kB (p65) mRNA in
16HBE14o- and CFBE41o-:Next we investigated if A20 induction
altered NF-κB(p65) mRNA levels (Figure 2). LPS stimulation
caused a significant induction of p65 1h after stimulation in
16HBE14o- (p<0.01 – p<0.001 vs. medium). Ikarugamycin (0.01
µM) was without significant effect on p65 mRNA. At 1 μM,
ikarugamycin alone induced p65 at 24h (p<0.01 vs. medium 24h)
and in the presence of LPS at 1h and 4h (both p<0.05 vs. LPS).
Quercetin alone showed no effect on p65 mRNA levels, but when
stimulated with LPS both concentrations of quercetin (0.1, 100
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Fig. 6. Effect of ikarugamycin, quercetin and ﬂuvas-
tatin on A20 and p65mRNA expression in PNECs from
(a) healthy controls and (b) patients with CF. Cells
were pre-incubated with ikarugamycin, quercetin or
ﬂuvastatin at the indicated concentrations (0.01 – 100
μM) and then stimulated (LPS, 10 μg/ml, 0- 24 h). A20
mRNA was determined by qRT-PCR and expressed as
A20/β-actin relative to internal control.Table 1: Se-
lected GEO gene expression data sets selected for
the connectivity mapping process.Table 2: Gene ex-
pression proﬁle of NF-kB/A20 related genes in CF
airway disease. Genes behaving in a similar way than
the target gene A20 were determined using linear
correlation analyses of the selected gene expression
data sets.
Table 3.
Drug C-score P-value Z-score Signiﬁcance Perturbation
stability
Drug class
Azacyclonol 0.3496 1.00E-05 4.8417 1 1 γ-Pipradol, ataractive drug
Ikarugamycin 0.4115 6.00E-05 4.1275 1 1 Macrolide type
Quercetin 0.33712 5.00E-05 3.8963 1 1 Flavenoid
Karakoline 0.43145 1.00E-05 3.8033 1 1 Alkaloid Diterpenoid
Fluvastatin -0.35325 1.00E-04 -3.8267 1 1 HMG-CoA reductase inhibitor
μM) significantly reduced p65 mRNA levels at 1h (p<0.01 vs LPS 1h). Similar to quercetin, fluvastatin alone showed no effect
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on p65 mRNA levels, but after LPS stimulation fluvastatin (0.1,
100 μM) significantly reduced p65 mRNA levels at 1h (p<0.001
and p<0.05 vs LPS 1h). In CFBE41o- LPS significantly induced
p65 at 1h, 4h and 24h (p<0.05-0.001 vs medium) and overall
CFBE41o- exhibited higher expression levels of p65 at 4h and 24h
than 16HBE14o- (Figure 2). Ikarugamycin was without significant
effect on p65 mRNA expression at any concentration or time
point, although overall expression levels appear higher at 1 μM,
when stimulated with LPS (Figure 2). In CFBE41o-, quercetin
(0.1 μM) did not affect p65 mRNA levels. At 100 μM, quercetin
significantly induced p65 (p<0.05: quercetin alone 100 μM 24h
vs. medium 24h and quercetin 100 μM + LPS 24h vs. LPS 24h).
Fluvastatin caused a significant reduction in p65 mRNA at both
concentrations and all time points after LPS stimulation (p<0.05
and p<0.01 for 0.1 μM+LPS vs. LPS; p<0.05 and p<0.01 for 1
μM+LPS vs. LPS) (Figure 2).
Effect of predicted drugs on A20 and p65 protein expression:
We then determined the effect of the drugs on cytosolic A20
and p65 protein by Western Blotting using the same selected
concentrations than before. Ikarugamycin (0.01 µM) inducedA20
protein in both 16HBE14o- and CFBE41o-, with less A20 protein
induction at 1 μM. Ikarugamycin also induced cytosolic p65 in
both cell types (Figure 3a). Quercetin treatment caused a strong
induction of A20 protein at both concentrations (0. 1, 100 μM)
in 16HBE14o- and to a lower degree in CFBE41o-. Quercetin
(100 µM) reduced cytosolic p65 in 16HBE14o- and in CFBE41o-
(Figure 3b). Fluvastatin did not induce A20 protein at either
concentration (0.1, 1 μM) in both 16HBE14o- and CFBE41o-
cells. Fluvastatin pretreatment reduced cytosolic p65 protein in
16HBE14o- cells though this was only apparent at the higher
concentration in CFBE41o- (Figure 3c).
Specificity of the drug effect on A20 mRNA expression using A20
siRNA: To confirm that the effect of the selected drugs is facili-
tated through A20 induction, we used siRNA to knock down A20
expression in 16HBE14o- cells as previously described (30). Cells
were pre-treated with quercetin or ikarugamycin prior to LPS and
IL-8 determined. Results (Figure 4) showed that in 16HBE14o-
LPS significantly induced IL-8 (p<0.05 compared to untreated
control), but when A20 is knocked down IL-8 increased further
(although not significantly different from LPS alone). When cells
are pre-treated with quercetin (100 μM) or ikarugamycin (1 μM),
the LPS induced IL-8 release was significantly reduced (p<0.05).
However, when A20 is knocked down IL-8 levels were not differ-
ent from LPS control (Figure 4).
Effect of A20 inducing drugs on PNECs Effect on IL-8 release:
LPS significantly induced IL-8 release from PNECs from non-
CF and CF patients (non-CF: p<0.01, CF: p<0.05, Wilcoxon
paired test, Figure 5). IL-8 release from CF PNECs was sig-
nificantly higher than from non-CF PNECs (600.6±62.8 pg/ml
vs. 315.8±36.1 pg/ml, p<0.01, Mann-Whitney test). In non-CF
PNECs (Figure 5a), pre-treatment with ikarugamycin at 0.01
μM, but not at 1 μM significantly reduced LPS induced IL-8
release (p<0.05). In quercetin and fluvastatin treated non-CF
PNECs only the higher concentrations tested (quercetin: 100 μM
and fluvastatin: 1 μM significantly reduced IL-8 release (p<0.01
and p<0.05, respectively, Figure 5a). PNECs from patients with
CF showed similar results with a significant IL-8 reduction at
the lower concentration of ikarugamycin (0.01 μM, p<0.01) and
the higher concentration of quercetin (100 μM, p<0.05). In CF
PNECs fluvastatin treatment significantly reduced IL-8 release at
both concentrations tested (0.1 μM, p<0.05; 1 μM, p<0.01,Figure
5b).
A20 induction in PNECs: In PNECs from non-CF control sub-
jects (Figure 6) LPS stimulation resulted in a rapid and significant
upregulation of A20 mRNA within 1h and a peak expression at
4h (p<0.05, LPS vs. medium at 1h and 4h). Ikarugamycin alone
at 0.01 μM increased A20 mRNA which reached significance at
24h (p<0.01) and in the presence of LPS this increase was signif-
icantly higher at 1h and 24h than LPS alone (p<0.05 and p<0.01
vs. LPS). Ikarugamycin (1 μM) had no effect on A20 mRNA
induction, either alone or in the presence of LPS. Quercetin
(0.1 μM) caused a significant induction of A20 compared to
medium control at 1h, 4h and 24h (all p<0.01) with expression
levels similar to those induced by LPS (Figure 6) and this was
maintained the presence of LPS, with a peak A20 induction at
4h. The higher concentration of quercetin (100 μM) significantly
induced A20 mRNA at 1h (p<0.05) and subsequent stimulation
with LPS resulted in significantly increased A20 mRNA levels
at 4h (p<0.05 vs LPS 4h). Fluvastatin treatment did not induce
A20 mRNA expression, but 1μM reduced A20 mRNA at 4h LPS
(Figure 6).
In CF PNECs LPS induced A20 mRNA expression was lower
than in non-CFPNECs, but inCFPNECsLPS induced significant
levels of A20 mRNA 4h after LPS (p<0.05 vs. medium 4h).
Ikarugamycin at 0.01 μM (alone and in the presence of LPS) had
no effect on A20 mRNA levels (Figure 6) but 1 μM ikarugamycin
significantly induced A20 mRNA at 4 and 24h alone (p<0.05
vs medium control) and in the presence of LPS (p<0.05 and
p<0.001 vs LPS). Similarly, quercetin treatment with the lower
concentration (0.01 μM) alone and in the presence of LPS had no
effect on A20 mRNA levels (Figure 6), while 100 μM quercetin
significantly induced A20 mRNA alone (4h, p<0.05 vs medium
control) and additionally above LPS induction (1h and 24h, both
p<0.05 vs LPS). Similar to non-CF PNECs, fluvastatin treatment
of CF PNECs had no significant effect on A20 mRNA expression
levels.
NF-κB (p65) induction in PNECs: PNECs from non-CF con-
trol subjects respond to LPS exposure with a significant increase
in NF-κB (p65) at 1h and 4h (p<0.001 vs medium control).
Thereafter, p65 mRNA expression returns to its corresponding
medium control value (Figure 6). PNECs from patients with CF
however show the expected high levels of p65 throughout the 24h
studied (p<0.01 at 1h, p<0.05 at 4h and 24h vs medium control)
(Figure 6).
In non-CF PNECs, ikarugamycin treatment alone did not
change p65 mRNA levels (vs medium control), but in the pres-
ence of LPS p65 mRNA was significantly reduced (p<0.05 at
1h, p<0.01 at 4h vs LPS). Overall the higher concentration
of ikarugamycin induced p65 mRNA levels with a significant
increase at 4h (p<0.05 vs medium control). However, in the
presence of LPS, p65 levels remained not significantly different
from those after LPS exposure at 1h and 24h, but were signifi-
cantly lower compared to LPS alone at 4h (p<0.05) (Figure 6).
The lower concentration of 0.01 μM quercetin alone did not
modify basal p65 mRNA. After subsequent LPS challenge p65
mRNA significantly decreased at 1h (p<0.01 vs LPS), but then
increased in a similar manner to LPS alone. However, 100 μM
quercetin alone significantly reduced p65 induction at 1h and 4h
(p<0.05 and p0.01 vs. medium control). In the presence of LPS
this reduction of p65 mRNA reached statistical significance at
4h and 24h (both p<0.05 vs LPS) (Figure 6). Fluvastatin (0.1
μM) induced p65 at 4h (p<0.05 vs. medium 4h), but p65 levels
remain significantly lower when LPS is added (p<0.05, vs LPS
at 1h and 4h). The higher concentration of fluvastatin (1 μM)
did not change p65 levels alone, but after addition of LPS, p65
mRNAwas initially reduced (1h p<0.05 vs LPS) but then induced
similarly to LPS alone (Figure 6).
When PNECs from patients with CF were pre-treated
with ikarugamycin, p65 levels dropped significantly at 0.01 μM
ikarugamycin in the absence or presence of LPS (p<0.05-0.01).
At the higher concentration of 1 μM p65 levels appeared lower,
but this only reached statistical significance at 1h (p<0.05 vs
LPS) (Figure 6). Pre-treatment of CF PNECs with quercetin did
not affect p65 levels alone at either concentration tested, but at
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0.1 μM quercetin in the presence of LPS significantly reduced
p65 at 24h (p<0.05 vs LPS). Treatment with 100 μM quercetin
significantly reduced p65 mRNA in the presence of LPS at all
time points (all p<0.05 vs LPS) (Figure 6). Fluvastatin alone
had no significant effect on p65 mRNA levels, but significantly
reduced LPS induced p65 at 1h, 4h and 24h (p<0.05 vs. medium
1h, 4h or 24h), while the higher concentration of fluvastatin (1
μM) showed no significant effect on basal or LPS induced p65
mRNA (Figure 6).
Discussion
Airways infection and the subsequent inflammation are delete-
rious for patients suffering from CF. Current drugs targeting the
mutated CFTR (potentiators/correctors) improve expression and
function of CFTR on epithelial surfaces and patients showed
improved lung function and reduced frequency of pulmonary
exacerbations, hospitalization and use of intravenous antibiotics,
bu augmented CFTR function failed to reduce inflammatory
markers in sputum (e.g. IL-1,-6,-8) (25) and heterogeneous re-
sponses to the treatment have been reported (26), suggesting
that CFTR correction/potentiation may not directly improve the
underlying compromised immune response. The negative NF-
κB regulator A20 (TNFAIP3) is reduced in CF airway epithelial
cells, basally and after LPS stimulation (23) and is associated
with markers of inflammation and decreased lung function (12).
A20 silencing increased TRAF6 and NF-κB activity (18), and
A20 over-expression had protective effects in airway inflamma-
tion in ‘asthmatic mice’ (27), suggesting that A20 augmentation
normalises the inflammatory response in the airways.
In order to find agents to induce A20 in CF we employed
sscMAP, which has been widely used in drug development uncov-
ering potential new indications for existing drugs as well as pre-
dicting side effects (28). Using disease specific publicly available
gene array data (GEOdata sets), we used connectivitymapping to
firstly identify the target gene (A20) related gene signature and to
secondly predict already licensed drugs to induce A20 expression.
We included a total of 76 gene array data from primary nasal
epithelial cells and cell lines commonly used in CF research (Table
1). Gene array databases were first selected in August 2013, but a
recent (Jan 2016) search revealed no further significant published
gene array data on CF (primary nasal) epithelial cells.
The applied linear regression model (Pearson’s correlation
coefficient) is an established robust method to identify the cor-
relates of a known gene expression estimating the strength of
a linear relationship between two random normally distributed
variables (29). The application of the linear regressionmodel with
GO (gene ontology) selection revealed a gene signature of 6 genes
additionally to the seed gene A20 (Table 2) and we confirmed that
the expression of these genes is similarly reduced in CF epithelial
cells, basally and after LPS stimulation (Figure 1). The identified
A20 correlates were ATF3, a transcriptional repressor that binds
to cAMP response elements (CRE); RAB5C, a small ubiqui-
tously expressed GTPase; DENND4A, which encodes the C-Myc
Promoter Binding Protein (MBP-1); POM121, a nuclear trans-
membrane protein and essential component of the nuclear pore
complex; ICAM1, a cell surface glycoprotein typically expressed
on endothelial and immune cells, especially during inflammation
and PSEN 1 (Presenilin 1), a catalytic component of γ-secretase
and a DREAM binding protein. Further descriptions of these
genes and their involvements in inflammation can be found in
the online appendix. These genes, as a combined gene signature,
were then input into the sscMAP process comparing the gene
expression of the gene signature with the gene expression in the
reference database (www.broadinstitute.org), which was obtained
from systematic microarray gene expression profiling.
SscMAP predicted a short list of drugs that should modify
the expression profile of the gene signature genes, including A20.
Those drugs included azacyclonol, ikarugamycin, quercetin and
karakoline (Table 3). Azacyclonol is a drug used in psychotic
individuals (30). We excluded azacyclonol, as its use requires
special permission through relevant government authorities. In-
terestingly, the anti-histamine terfenadine is metabolised to aza-
cyclonol and terfenadine (31). Karakoline is a highly toxic plant
diterpenoid (32) and the pharmacological effects of preparations
of Aconitum roots are attributed to diterpenoid alkaloids (33).
The anti-inflammatory activity of gibberellin (GA3), also a plant-
derived diterpenoid, is mediated through A20 induction (24).
We therefore selected ikarugamycin and quercetin for further
studies.
Ikarugamycin is a macrolide antibiotic with cytostatic effects
against Gram-positive bacteria. We show that ikarugamycin ex-
hibits anti-inflammatory properties in LPS stimulated airway
cells. In 16HBE14o- ikarugamycin showed a dose-dependent
reduction of LPS-induced IL-8 release (supplement S4), through
induction of A20 and reduction of p65 (Figure 2). 16HBE14o- and
CFBE41o- did not show reduced cell viability at concentrations
lower than 1 μM, higher concentrations increased LDH release
suggesting a cytotoxic effect (supplement S2). CFBE41o- appear
more sensitive to ikarugamycin treatment (supplement S4), which
made it not possible to calculate a meaningful relative IC50
value (supplement S3), although p65 protein expression was not
increased (Figure 2). InHL-60 cells, ikarugamycin reduced cell vi-
ability and increased DNA fragmentation starting at 0.1 µM(IC50
of 0.22 μM), while MCF-7 cells and peripheral blood mononu-
clear cells showed higher resistance. Furthermore, ikarugamycin
treatment of HL-60 cells caused a significant caspase activation,
increase in intracellular calcium and p38 MAP kinase activation
(34). However, investigating the pro-apoptotic mechanisms in
bronchial epithelial cells was beyond the scope of this study.
Nonetheless, our ikarugamycin data at near cytotoxic levels add
valuable information: Firstly, sscMap correctly predicted that
ikarugamycin would induce A20 mRNA but sscMap does not
predict the physiological effect of the gene induction. CF cells
overall show a limited ability to induce A20, however, our results
show that – given the right stimulus – CF cells are indeed able
to induce A20 mRNA and the high induction of A20 at near
cytotoxic levels may be able to counteract the pro-apoptotic
stimulation of ikarugamycin.
Quercetin, a flavonoid, is known for its anti-inflammatory ef-
fects. In vivo studies have shown antioxidant, anti-inflammatory,
anti-tumour and even anti-infectious properties of quercetin,
which are promoted through its effects on signalling pathways
such as NF-κB (35). In lung epithelial cells, quercetin inhibited
IL-1 and TNF-α induced IκBα degradation and NF-κB activity
throughmodification of theMAPK pathway (AP-1) (36). SscMap
correctly predicted that quercetin can induce A20mRNA, adding
a new mechanism for the anti-inflammatory effects of quercetin.
It also significantly reduced LPS-induced IL-8 release in both
cell types with a relative IC50 of 0.15 and 0.04 μM in 16HBE14o-
and CFBE41o-, respectively. Quercetin at concentrations up to
1000 μM did not show any cytotoxicity, although in neuronal cell
cultures quercetin higher than 100 μMwas cytotoxic (37). Within
the in vivo antioxidant network, quercetin has been described to
be oxidised and to yield an ortho-quinone, which, in absence of
reducing glutathione, can oxidise protein thiols impairing enzyme
activities (38). We have not investigated the antioxidant status of
our cell culture, but we took precautions to minimise oxidation
when preparing our quercetin dilutions.
To further investigate the A20-dependent mechanism of the
anti-inflammatory action of quercetin and ikarugamycin, we used
A20 knock down in 16HBE14o-. As previously described for the
A20 inducing anti-inflammatory compound gibberellin (24), we
were able to confirm that the anti-inflammatory effect of the
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predicted drugs was indeed mainly mediated by the induction of
A20.
We also tested fluvastatin, which was predicted not to affect
or reduce A20 gene expression (negative z-score). Although
fluvastatin exerted anti-inflammatory effects (IL-8) in both cell
lines, our data show that this was not mediated by the induction
of A20 (mRNA), clearly confirming the sscMap prediction. In
asthma, fluvastatin inhibits eosinophil adhesion to ICAM-1 (39)
and fibroblast proliferation (40). Using similar concentrations we
did not observe any reduced proliferation. Fluvastatin at a con-
centration range similar to those we used, reduced basal and LPS-
induced IL-8 release from LPS stimulated whole blood cells, with
CF cells appearing more sensitive to fluvastatin than control cells
(IC50: 19.1 μM in non-CF cells, 4.6 μM in CF blood cells) (41).
In isolated LPS-stimulated peripheral blood monocytes from
patients with chronic kidney disease fluvastatin had a significant
anti-inflammatory effect (IL-8, IL-6) at a concentration range of
0.0001–1 μM (42). Patients with heart transplants receiving 40 mg
fluvastatin/day for 4 weeks showed a significant reduction in total
cholesterol levels and amaximumblood fluvastatin concentration
of 2.11 and 3.77 μM. These studies suggest that we have covered a
physiologically relevant range of fluvastatin. However, fluvastatin
metabolism may be affected by concomitant therapies, especially
substances competing with cytochrome enzymes and in such cases
fluvastatin levels may need to be monitored (43). Any reactions
with other therapies (as they would appear in patients with CF)
were not investigated in our manuscript as they would have been
beyond the scope of the study.
Similar to ikarigamycin, fluvastatin has been described to
have pro-apoptotic effects e.g. in human lymphoma cells, hu-
man smooth muscle cells and in rat neonatal cardiac myocytes
or rat vascular smooth muscle cells (44, 45), mediated through
activation of caspase-3, reactive oxygen species and activation of
p38 MAPK (44, 55). However, statins, through their inhibition of
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), but not through
induction of A20, may still have therapeutic potential in airway
and systemic inflammation in CF (41).
Overall, our study shows that connectivity mapping (sscMap)
can predict A20 inducing drugs. Pre-treatment of cells with both
ikarugamycin and quercetin reduces LPS-induced IL-8 secretion
by induction of A20. In non-CF PNECs both drugs upregulated
A20 and reduced IL-8 and p65 mRNA at lower concentrations
than in cell lines. CF PNECs, however, have a reduced and
delayedA20 inducing response to LPS and to the tested drugs and
a significant A20 induction appears at the higher concentration of
the drugs tested, which might be near to the cytotoxic effect. A20
reduces apoptosis (46, 47) and mutational loss of A20 resulted in
rapid apoptosis and inflammation in hematopoietic cells (48). We
did not determine markers of apoptosis in our study, but the huge
increase in A20 mRNA may indicate a possible counteraction
to pro-apoptotic changes in response to ikarugamycin treatment.
Of particular interest, this may indicate a higher susceptibil-
ity/sensitivity of CF cells to pro-apoptotic stimuli.
Our study has several limitations. Firstly, for the sscMAP
process a huge number of gene array samples are required and
although the database search gave a high number of initial results,
upon detailed inspection several gene array studies could not
be included. Connectivity mapping uses gene array data run on
Affimetrix platforms and we selected those performed on these
platforms. Several published gene array studies were performed
in cell lines. However, the majority of samples selected were
PNECs (n=40), but we also included data from cell lines. Fur-
thermore, every published dataset has been performed using a
specific experimental design with respect to treatments and time
points.We selected experiments that used either no stimulation or
exposure to P.aeruginosa LPS or to P.aeruginosa itself. A sample
size of 50-100 individual samples is a statistically acceptable sam-
ple size to produce an unbiased result and we used 76 individual
gene array samples.
Secondly, the reference database was generated using differ-
ent cell lines: MCF7, HL60, PC3 and SKMEL5. Although all of
human origin, none of these cell lines are airway derived. We
therefore confirmed the effect of the predicted drugs in airway
relevant and disease specific cell lines, determined an effective
drug concentration in our disease model and confirmed their
effect in primary cells. Additionally, factors such as the interaction
between various signalling pathways and the interplay between
genes can affect the functions of the predicted and validated drugs
when used in humans.
The aim of our study was to investigate the potential of
sscMap to predict A20-inducing drugs from a list of drugs already
licenced for the use in humans to make them available for drug
repositioning. As a proof of concept we have focused on the
LPS induced expression of A20, p65 and cytokines IL-6 and IL-
8. However, in addition to its direct regulation of TLR-induced
NF-κB activation, A20 is also involved in the negative regula-
tion of the of NLRP3 inflammasome via TLR3/4-(TRIF)-RIPK3
(49) may also inhibit inflammation induced regulated necrosis
(necroptosis) via RIPK3 (50), adding further levels of action and
complexity to the anti-inflammatory action of A20. Therefore,
future work analysing further NF-κB driven cytokines such as
TNFα and IL-1β would also indicate if the predicted drugs are
able to modify A20 action on the inflammasome.
Summary
To date there is still a need for alternative anti-inflammatory
drugs for patients with CF as restoring CFTR function with
potentiators and correctors does not directly affect the inherent
innate immune defect. The exaggerated inflammatory response
is in part due to the lack of the NF-κB regulator A20 and
pharmacological induction of A20 is anti-inflammatory. We have
shown here that sscMap is a potent tool to predict effective drugs
that can modify A20 without totally inhibiting NF-κB. This is
particularly important in the clinical setting as pharmacological
suppression of inflammation may increase the incidence of in-
fective exacerbations (51). In addition, A20 inducing drugs have
to be carefully adjusted as in addition to the A20 induction e.g.
ikarugamycin can be pro-apoptotic. A20 inhibits TNF-induced
pro-apoptotic signalling by inhibiting both, the activation of cas-
pase 8 and the activation of c-Jun (52). However, neither the drug
induced pro-apoptotic mechanisms nor the A20 induced anti-
apoptotic mechanisms have been investigated in this study, but
our observation of cytotoxicity despite high anti-apoptotic A20
mRNA levels may suggest an overriding mechanism. Therefore,
while sscMap successfully predicts drugs tomodify A20, the effect
of the candidate drugs must to be confirmed in a suitable model
system to optimise treatments.
Our study also suggests that pharmacological induction of
A20 may be less efficient in CF airway cells, but given the appro-
priate stimulation, A20 induction is indeed possible. Tiruppathi et
al. recently showed that A20 induction may be regulated not only
via NF-κB, but also through the opposing effects of the repressor
DREAM and transcription factor USF1 (53). Future work will
investigate if modifying the balance between A20 repressor and
transcription factor in CF can more efficiently re-establish A20
induction.
Materials and Methods
Selection of Gene Array data
A search of PubMed GEO data sets (http://www.ncbi.nlm.nih.gov/gds/)
was performed in August 2013 using the search terms “Cystic Fibrosis”,
“epithelial cells”, “airways” and “primary cells”. Data sets that passed the search
criteria and were compatible to Affymetrix Human Genome U133A Array
were selected.
Connectivity Mapping (sscMap)
Gene expression proﬁles were generated using Afﬁmetrix Gene chip
Microarray and the relative expression of treatment vs. control was sorted
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in descending order giving rise to 22000 rank ordered genes and their
expression.
Determination of the gene signature
The correlation coefﬁcient r demonstrates the association between A20 and
other genes, either in a positive or negative direction. The signiﬁcance of
the observed correlations was measured by calculating the corresponding p
values and applying a stringent p value threshold 1/N where N is the number
of genes analysed. The signiﬁcant r values were selected as correlates of
A20. Gene ontology (GO) enrichment analysis (http://geneontology.org/)
was then applied to further ﬁlter the A20 correlates identifying those
related to NF-κB. The subsequent gene signature (including A20) was used
as the input query to evaluate the connection between them and the
reference proﬁles (GEO, Accession Number GSE5258) (8). Based on the
principles of Lamb’s connectivity mapping, we used a simpler and more
robust method (9, 10), called sscMap (statistically signiﬁcant connections'
map), to determine the connections between the gene signature and the
reference proﬁle. The similarity between the gene signature and each
gene expression reference proﬁle was assessed via a connection score.
Connection scores are a function of expression proﬁle and the query gene
signature, which is expected to reﬂect the underlying connection between
them.
The sscMap applies a robust and improved scoring system based on the
following formulae:
(Where gi represents the i th gene in the signature, s(gi) is its signed rank
in the signature, and R(gi) is this gene's signed rank in the reference proﬁle).
To calculate the p value, after calculating the connection strength between
a gene signature and the reference proﬁle a large number of random
gene signatures are created and the same number of connection scores
are calculated and the proportion of scores higher than the observed score
in absolute values is the p value. In addition to controlling false positives,
sscMap is extended to measure the stability of the connections discovered by
gene signature perturbation. In order to implement this, one gene is left
out from the gene signature to derive ‘perturbation’ gene signature and
the changes in the signiﬁcant connections were observed. The connections
which stay stable over the changes were given the perturbation stability
score, deﬁned as the fraction of times a drug remained signiﬁcant under
the perturbation process (54).
Cell Culture
The bronchial epithelial cell lines 16HBE14o- (control) and CFBE41o- (CF,
F508del/F508del), obtained from D. Gruenert, UCSF, USA were cultured as
described (32). Primary nasal epithelial cells (PNECs) from CF patients (all
F508del/F508del, n=5) and healthy volunteers (n=5, informed consent given,
research ethics approval 07/NIR02/23) were cultured as previously described
(55). Control participants did not have any acute airways disease at the time
of sampling, or a history of any chronic airways inﬂammation.
Cell culture stimulations
Cells were exposed to the selected drugs (ikarugamycin, quercetin,
ﬂuvastatin (all Sigma-Aldrich, SML0188, Q0125, SML0038, 0.01–1000 µM) at
0-1000 μM for 1 h prior to LPS stimulation (P. aeruginosa LPS, Sigma-Aldrich,
L9143, 10 µg/mL, up to 24h). Stock solutions of the drugs were kept at -20°C
for up to 3months. Tominimise oxidation or degradation of the compounds,
the working dilutions were freshly prepared.
Determination of LPS induced cytokine release (IL-6 and IL-8)
IL-6 and IL-8 in cell-free culture supernatants were measured by a com-
mercially available ELISA (PeproTech EC Ltd.) according to themanufacturer’s
instructions.
LDH Cytotoxicity assay
Lactate dehydrogenase (LDH) release into cell culture supernatants was
determined using a LDH-Cytotoxicity Assay Kit (BioVision Ltd.) according to
the manufacturer’s instructions.
Real time qPCR
Total RNA was extracted (GenElute™, RTN350, Sigma-Aldrich) and
quantiﬁed. Equal amounts of RNA (250 ng) were reverse transcribed into
cDNA (High-Capacity cDNA Reverse Transcription Kit, Applied Biosystems™)
and quantitative RT-PCR performed (LightCycler thermal cycler system,
Roche). Expression of A20, p65 and β-actin were assessed using primer se-
quences previously described (23) and given in supplement table S1. Relative
expression to β-actin was calculated as ΔΔCt. Jurkat cell cDNA acted as an
internal calibrator for all experiments and was used to determine differences
in basal gene expression.
Western Blotting
Cytosolic protein expression was determined by Western Blotting after
extraction in RIPA buffer containing protease inhibitors (cOmplete™, Mini,
Roche). Lysates were separated by SDS-PAGE and PVDF membranes incu-
bated with 1 µg/ml primary antibody: A20 (ab74037, Abcam); p65 (C-20,
Santa Cruz Biotechnology), washed, incubated with appropriate horseradish
peroxidase-conjugated antibody and visualized on a BioRadChemi Doc XRS
system (BioRad). Anti-GAPDH-HRP (ab-9484, Abcam) was used as a loading
control.
Transfections
16HBE140- were seeded at 4x104 cells/well and allowed to attach
overnight. Custom FlexiTube siRNA (QIAGEN, UK) was designed against
TNFAIP3 and both cell lines transfected with 50 nM siRNA and Lipofectamine
Transfection Reagent (Invitrogen, UK) over 72h. All experiments included
mock transfection and scrambled controls. Gene silencing was assessed by
qPCR as described above with knockdown of 74% ± 7.2; n=5) achieved.
Statistical analysis
All data are presented as the means ± SEM. Differences between groups
were analysed using the Kruskal-Wallis non-parametric ANOVA with Dunn’s
post-test (*p<0.05, **p<0.01 and ***p<0.001). $ denotes a signiﬁcant differ-
ence compared to medium control, while * denotes signiﬁcant differences
between groups (CF vs. non-CF, comparing the same time points or LPS vs.
treatment + LPS). The logarithmic inhibitor concentration versus the relative
IL-8 response achieving a 50% inhibition was calculated as the relative IC50.
GraphPad Prism (La Jolla, California) was used to plot graphs and to analyse
the data.
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